23 October – Webinar in connection with Q3 interim report
Alligator hosted a webinar and conference call for investors, analysts on 23 October 2025 where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the interim report. The presentation was followed by a Q&A session.
The call was held in English. Attendees can request a reply at ir@alligatorbioscience.com.
19 August – R&D event
Alligator hosted a virtual R&D Day on Tuesday, 19 August 2025 providing an in-depth update on Alligator’s R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1–15 September 2025).
LATEST NEWS
Alligator Bioscience to present new OPTIMIZE-1 data on mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026
Lund, Sweden – 9 January 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin …
Alligator Bioscience carries out a directed issue of units to guarantors and a directed issue of warrants to Fenja Capital in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, …
Alligator Bioscience announces final outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, …